The most common treatment-related adverse events of were bone marrow suppression, including 80.3% (53/66) neutropenia, 50% (33/66) ALT elevation, 25.8% (17/66) anemia, 6.1% (4/66) thrombocytopenia, 1.5% (1/66) leukemia, 1.5% (1/66) in primary chemotherapy patients, 86.2% (25/29) ALT elevation, 82.8% (24/29) neutropenia, 31% (9/29) thrombocytopenia, 10.3% (3/29) anemia, and 3.4% (1/29) epilepsy in salvage chemotherapy patients, respectively. The gene discussed is GPT; the disease is neutropenia.